Research suggests BPC-157 naturally migrates to areas of tissue damage regardless of injection location
However, long-term human safety data from controlled clinical trials is limited
The second camp centered on the benefits of the peptide, and that both McKnight and Hanes had used BPC-157 in a medical manner as opposed to one for performance enhancement
Annual Review of Nutrition , 18 , 3961
Cardiovasc Res 36:276281 Masaki I, Yonemitsu Y, Yamashita A, Sata S, Tanii M, Komori K, Nakagawa K, Hou X, Nagai Y, Hasegawa M et al (2002) Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2